Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeoGenomics (NEO)
NASDAQ:NEO
Earnings Data
Report Date
May 06, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
>-0.01Last Year’s EPS
-0.02Same Quarter Last Year
Moderate Buy
Based on 12 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 18, 2025
|% Change Since: -17.75%
|Next Earnings Date:May 06, 2025
Earnings Call Sentiment|Positive
NeoGenomics demonstrated strong revenue growth and financial improvement, particularly in its NGS segment and adjusted EBITDA. However, challenges in the pharma segment and ongoing legal issues with RaDaR tempered the overall positive performance.Company Guidance
During the NeoGenomics Fourth Quarter and Full Year 2024 Financial Results Conference Call, the company provided guidance for 2025, highlighting expectations for full-year revenues between $735 million and $745 million, representing 11% to 13% growth. The adjusted EBITDA is projected to be between $55 million and $58 million, indicating an improvement of 38% to 45%. The company has been experiencing robust growth, with clinical testing volumes increasing by 9% and revenue per test rising by 5% compared to the prior year. NeoGenomics has grown revenue double-digits for nine consecutive quarters, with adjusted EBITDA turning from a negative $48 million in 2022 to a positive $40 million in 2024. The company's adjusted gross margins improved to 48%, the highest in 20 quarters, and they served nearly 700,000 patients in 2024. Looking ahead, they aim to achieve top-line growth of 12% to 13% annually and expect to serve 1 million patients annually by 2028.Consistent Revenue Growth
NeoGenomics reported revenue growth for nine consecutive quarters, reaching $172 million in Q4 2024, representing an 11% increase over the prior year.
Significant Improvement in Adjusted EBITDA
Adjusted EBITDA improved from a negative $48 million in 2022 to a positive $40 million in 2024, with a 27% improvement in Q4 2024 alone.
Growth in NGS Testing
NGS revenue grew by 24% in Q4 and 34% for the full year, now representing over 30% of total revenue.
Gross Margin Expansion
Adjusted gross margins improved to 48% in Q4, the highest in five years.
Increased Patient Reach
NeoGenomics served nearly 700,000 patients in 2024, with a goal to reach 1 million annually by 2028.
---
NEO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NEO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 18, 2025 | $14.42 | $12.40 | -14.01% |
| Nov 05, 2024 | $14.14 | $14.93 | +5.59% |
| Jul 29, 2024 | $14.64 | $17.27 | +17.96% |
| Apr 30, 2024 | $15.22 | $13.92 | -8.54% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does NeoGenomics (NEO) report earnings?
NeoGenomics (NEO) is schdueled to report earning on May 06, 2025, TBA Not Confirmed.
What is NeoGenomics (NEO) earnings time?
NeoGenomics (NEO) earnings time is at May 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NEO EPS forecast?
NEO EPS forecast for the fiscal quarter 2025 (Q1) is >-0.01.
---
